Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Commercial Life Catches up With Solazyme Inc (SZYM)

Page 1 of 2

Throw all of your revenue projections out the window for now. Renewable oils manufacturer Solazyme Inc (NASDAQ:SZYM) started out the week with some bad news. The company announced that it was dissolving its joint venture with Roquette Freres — a mutual agreement — after the two had “divergent views on an acceptable commercial strategy, timelines for manufacturing, and the marketing of joint venture products”. Apparently, Roquette — along with the rest of Europe — is not too thrilled about using genetically modified organisms in its food.

Solazyme Inc (NASDAQ:SZYM)

It marks the first time that the company has had a major setback and serves as a reminder to stay on your toes when investing in the turbulent industrial biotech industry. While it certainly isn’t good news in the short or long terms, it isn’t all bad news, either. I know that sounds hard to believe given the dismal view investors got of the inner workings of the joint venture Monday morning. However, there are several things investors and potential investors need to know after the change in circumstances.

The bad news
Well, Solazyme Roquette Nutritionals (SRN) is no more. What does that mean? The commercial facility being developed in Europe — which was owned 100% by Roquette, anyway — is no longer going to contribute oils for the company’s top and bottom lines. A phase-two expansion of the facility to 5,000 metric tons (MT) of annual capacity was under way and expected to be ready for ramp-up this month. A phase-three expansion could have boosted total annual nutritional oils capacity to 50,000 MT in later years.

That missing production is a slight blow in the short term. SRN was only going to contribute 2,500 MT of oils by the end of 2014 and, if expanded further, only 25,000 MT. By contrast, Solazyme Inc (NASDAQ:SZYM) will capture much larger production volumes with its partner Archer Daniels Midland Company (NYSE:ADM) and in its joint venture with Bunge Ltd (NYSE:BG)

Biorefinery Nameplate Capacity Nameplate Operations By Solazyme Capacity
Clinton, Iowa 20,000 MT Mid-2015 20,000 MT
Moema, Brazil 100,000 MT Early to mid-2015 50,000 MT

Source: SEC filings

The Clinton facility will eventually be expanded to 40,000 MT and 100,000 MT — all of which will be owned by Solazyme Inc (NASDAQ:SZYM). The Moema facility, being jointly developed with Bunge Ltd (NYSE:BG), will not be expanded under current agreements. However, the two are expected to add an additional 200,000 MT of capacity at other locations (half-owned by Solazyme Inc (NASDAQ:SZYM)) to their venture by 2016, meaning that it would be operating at full nameplate capacity by mid-2017 at the latest.

Total annual nameplate production without SRN will only drop from 72,500 MT to 70,000 MT by the time the middle of 2015 rolls around. Longer-term production, including planned but uncommitted capacity with Bunge Ltd (NYSE:BG), will be axed from 275,000 MT to 250,000 MT. That represents about $75 million-$125 million in annual revenue in the long term (2013 revenue will not be affected).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!